Google
EFTR — EFFECTOR THERAPEUTICS INC (Healthcare >> Biotechnology)
EFTR FAQ
What is EFTR's ROE?
EFFECTOR THERAPEUTICS INC reports a Return on Equity (ROE) of -4,187.42%.
What is EFTR's dividend yield?
EFFECTOR THERAPEUTICS INC offers a dividend yield of 0.00%.
What is EFTR's Deepscope Quality Score?
Deepscope rates EFTR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EFTR?
Deepscope's AI Timing Score for EFTR is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EFTR belong to?
EFFECTOR THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
EFTR Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 58 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / 4.90
|
| Earning Per Share | -7.37 |
| PE / Sector |
N/A / 18.25
|
| PEG or PE/Growth / Sector |
N/A / 0.62
|
| Average 1M Daily Value |
1.880445000000
GREAT
|
| Average 1W Daily Value |
0.000000000000
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
37% |
| Khả năng kiếm lợi nhuận |
|
50% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-16 09:58:57 |
| Symbol | EFTR |
| Name | EFFECTOR THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 4.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 8,995.97 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 142 North Cedros Avenue, Solana Beach, CA, United States, 92075
Phone: 858 925 8215
Website: https://effector.com
Sector: Healthcare >> Biotechnology
Description: eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. It has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
